gb HEMO FXIII (V34L)
Detection method:
allelic discrimination, real-time PCR
This in vitro diagnostic kit is intended for detection of mutation V34L in fibrin stabilizing factor XIII in human genomic DNA. Detection is based on real-time polymerase chain reaction (qPCR) using fluorescently labelled probes (allelic discrimination).
Clinical implications of the CE IVD kit
Factor XIII, also called fibrin stabilizing factor, is a proenzym circulating in plasma. Its active form stabilizes the fibrin network by catalytic formation of covalent bonds between fibrin molecules and other proteins (alpha-2-antiplasmin, fibronectin, collagen), thereby protecting the coagulum against fibrinolysis.
FXIIIa plays an important role not only in hemostasis but also during wound healing and in maintaining pregnancy. The presence of the V34L has a protective effect against myocardial infarction and venous thrombosis. On the other hand, it is also stated that the presence of this polymorphism is associated with an increased risk of recurrent pregnancy loss in the first trimester, which was also found in connection with the PAI-1 (4G/5G) mutation.
Parameters of the real-time PCR diagnostic kit
- ready-to-use assay
- sample concentration 1-100 ng/µl
- positive and negative controls included
- FAM and HEX channels detection
- identical amplification profile as gb HEMO, gb GENETIC, gb PHARM kits
Validated for:
ABI 7500/7500 Fast (ABI)
ABI 7900HT (ABI)
AriaMx (Agilent Technologies)
CFX96/96Touch (Bio-Rad)
iCycler iQ5 (Bio-Rad)
Light Cycler 480/Cobas z480 (Roche Diagnostics)
MIC (BMS)
QuantStudio 5 (Applied Biosystems)
RG 3000 (Corbett Research)
RG 6000/Q (Corbett Research/Qiagen)
SmartCycler (Cepheid)